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SUMMARY
The gut microbiota’s function in regulating health has seen it linked to disease
progression in several cancers. However, there is limited research detailing its in-
fluence in breast cancer (BrCa). This study found that antibiotic-induced perturba-
tion of the gut microbiota significantly increases tumor progression in multiple
BrCa mouse models. Metagenomics highlights the common loss of several bacte-
rial species following antibiotic administration. One such bacteria, Faecalibacu-
lum rodentium, rescued this increased tumor growth. Single-cell transcriptomics
identified an increased number of cells with a stromal signature in tumors, and
subsequent histology revealed an increased abundance of mast cells in the tumor
stromal regions. We show that administration of a mast cell stabilizer, cromolyn,
rescues increased tumor growth in antibiotic treated animals but has no influence
on tumors from control cohorts. These findings highlight that BrCa-microbiota in-
teractions are different from other cancers studied to date and suggest new
research avenues for therapy development.
INTRODUCTION
As of 2020, breast cancer (BrCa) was the most frequently diagnosed cancer type globally. It was estimated
to contribute 11.7% of the 19.3 million new cancer diagnoses and 6.9% of the 10 million cancer-related fa-
talities in 2020 (Sung et al., 2021). While10% of BrCa cases are linked to hereditary or somatic mutations in
tumor suppressor genes, such as BRCA1 and BRCA2, the vast majority of onset cases are the result of life-
style and environmental factors (Perez-Solis et al., 2016). Smoking, alcohol consumption, and diet have all
been associated with the onset of BrCa, as well as being major contributors to disruption of gut homeosta-
sis (Bray et al., 2018; Perez-Solis et al., 2016; Teng et al., 2021; Zitvogel et al., 2017).
The gut microbiota comprises a diverse and complex array of microbes, which play an integral role in main-
taining human health. Under normal healthy conditions, these microbes regulate the immune system, both
locally and at sites distant from the gut (Kelly and Mulder, 2012). However, when the gut environment is
altered unfavorably, following an antibiotic course for example, the microbial community profile is shifted
or disturbed, and gut homeostasis is lost (Hughes et al., 2017; Zitvogel et al., 2017). Alterations in the gut
microbiota are associated with an array of molecular and physiological changes. Inflammatory signaling
pathways can be amplified or dampened depending on changes in bacterial metabolite production,
and such alterations have been associated with a variety of diseases, including cancer (Rooks and Garrett,
2016; Zitvogel et al., 2015). In colorectal cancer, a reduction in short-chain fatty acid (SCFA) production by
Roseburia resulted in a proinflammatory cascade that promoted cancer progression in an in vivo mouse
model (Wu et al., 2013). Additionally, a study of the gut microbiota composition of premenopausal patients
with BrCa identified a reduction in the abundance of SCFA producing Pediococcus species compared to
normal premenopausal women. The same study demonstrated the anti-cancer effects of butyrate and pro-
pionate on human BrCa cells in vitro (He et al., 2021). Contrastingly, inoculation of mice harboring
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subcutaneous melanomas with Bifidobacterium, a known beneficial ‘‘probiotic’’ genus, has been shown to
amplify the anti-tumor effect of an anti-PD-L1 immunotherapy through the priming of CD8+ T lymphocytes
(Sivan et al., 2015). Studies like these demonstrate the microbiota’s integral role in regulating local and sys-
temic responses to cancer.
Since the discovery of penicillin in 1928, antibiotics have become an extremely effective way of preventing and
fighting bacterial infections (Aminov, 2010). Nevertheless, with the evolution of antibiotic-resistant bacterial
strains and an emerging understanding of the risks associated with antibiotic-inducedmicrobiota disturbances,
the frequency of their use has become increasingly controversial (Aminov, 2010; Becattini et al., 2016). The use of
antibiotics in patients with BrCa is a common practice, yet their clinical benefit is under debate (Jones et al.,
2014; Ranganathan et al., 2018). Additionally, the resultant alterations in the gut microbiota created by their
use raise concerns over potential impacts onmetabolism and inflammation that might drive tumorigenesis (Ed-
wards et al., 2014; Tremaroli and Backhed, 2012). While the consequence of antibiotic use has been somewhat
examined in other cancers, studies in BrCa are really just beginning.
A recent study by Buchta Rosean and colleagues showed that antibiotic-induced disturbances of the gut micro-
biota drive metastatic dissemination of an estrogen receptor-positive (ER+), luminal Amouse model of BrCa by
inducing increased stromal fibrosis and intra-tumoral macrophage infiltration (Buchta Rosean et al., 2019). How-
ever, given the prevalence and heterogeneity of the disease and its variable responses to therapies, it is vitally
important to understand howantibiotic-inducedgutmicrobiota changes influence progression across the spec-
trum of BrCa subtypes. Using clinically relevant orthotopic mouse BrCa models of luminal B and basal-like
subtypes, as well as the same luminal A model used by Buchta Rosean et al. (2019), we identified a significantly
increased rate of primary tumor growth in animals subjected tobroad-spectrum antibiotics. In contrast to the re-
sults describedby Buchta Rosean et al. (2019), we found little variation in gross immune cell infiltration in primary
tumors from animals under continuous antibiotic treatment. However, bulk and single-cell transcriptomics re-
vealed alterations in stromal cell populations in tumors from antibiotic treated mice; we detected an increased
number of mast cells in tumor stroma in these animals and demonstrated that mast cells may be drivers of the
accelerated tumor progression following antibiotic-inducedmicrobiota disturbances. Moreover, metagenomic
analysis of the caecal contents of antibiotic-treatedmice revealed a loss of several commensal bacterial species
which correlated with elevated tumor growth. Re-supplementation of antibiotic-treated mice with one of these
species, Faecalibaculum rodentium, restored tumor growth to control levels.
RESULTS
Treatment with broad-spectrum antibiotics results in severe perturbation of the gut
microbiota and acceleration of breast tumor growth
We set out to investigate the role of the gut microbiota in regulating BrCa progression. We primarily em-
ployed an orthotopic mammary fat pad injection model using the PyMT-BO1 cell line, which exhibits a
luminal B intrinsic phenotype (Su et al., 2016), representing a common (20–40%) and somewhat aggressive
form of BrCa (Metzger-Filho et al., 2013).
Prior to tumor cell injection, themicrobiota of animals were depleted using a cocktail of antimicrobials con-
sisting of vancomycin, neomycin, metronidazole, amphotericin, and ampicillin (VNMAA) (Croswell et al.,
2009; Reikvam et al., 2011). To maintain a continuous knockdown of the microbiota and to prevent off-
target effects from bacterial regrowth, we continued antibiotic treatment throughout the experimental
period. Following the regimen illustrated in Figure 1A, animals treated with VNMAA had significant micro-
biota knockdown after 5 days of treatment, and this knockdown persisted throughout the experimental
time course (Figure 1B). Notably, these animals exhibited significantly accelerated tumor growth relative
to control (water treated) counterparts (Figure 1C). When comparing treatment groups, no apparent differ-
ences in histopathology or vascular density were observed in tumors subjected to H&E and anti-endomucin
immunohistochemical staining, respectively (Figures S1A and S1B). However, the number of Ki67 positive
cells was increased in tumors from VNMAA-treated animals, suggesting that the antibiotic regimen pro-
moted tumor cell proliferation (Figure 1D). Using a similar treatment regimen, we also observed enhanced
tumor growth in orthotopically implanted models using EO771 cells, which more closely resemble basal-
like BrCa (Ewens et al., 2005), and in BRPKp110 cells, which resemble poorly metastatic luminal A-like
BrCa (Allegrezza et al., 2016) (Figure 1E), suggesting that antibiotic-induced knockdown of the microbiota
drives disease progression across multiple BrCa subtypes. Using the PyMT-BO1 model, we also explored
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Figure 1. VNMAA-induced microbiota depletion accelerates BrCa progression
(A) Schematic of PyMT-BO1 experimental timeline; antibiotics were administered onMonday, Wednesday, and Friday for
the duration of the experiment until cessation 18 days after orthotopic injection.
(B) Representative agarose gel images of 16S rRNA signatures of DNA extracted from fecal samples and amplified by
PCR; DoT = days of treatment.
(C) Bar plot (mean G s.e.m.) showing endpoint tumor volumes from VNMAA- and water-treated control animals (N = 3).
(D) Representative photomicrographs of Ki67 positive staining in PyMT-BO1 tumors following control or VNMAA
treatments and the bar plot (mean G s.e.m.) quantification of the average percentage of positive cells per frame (two
frames per tumor section) (N = 1, n = 5 per condition). Scale bar represents 20 mm.
(E) EO771 and BRPKp110 tumor volumes following VNMAA treatments. The experimental setup was the same as that
presented for PyMT-BO1 cells (A), but tissue harvest was performed on days 26 and 21 after orthotopic cell injection,
respectively. Bar plots (mean G s.e.m.) show endpoint volumes of the EO771 tumors (left) (N = 2) and BRPKp110 tumors
(N = 1).
(F) Schematic of PyMT-BO1 metastatic studies (left), antibiotics were administered thrice weekly to experimental
endpoint. The bar plot (mean G s.e.m.) shows tumor volumes at point of resection (right) (N = 1).
(G) Bar plot (mean G s.e.m.) showing days to tumor resection at ~600 mm3.
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primary tumors resected at 600 mm3 (via external caliper measurements), and lungs harvested and pro-
cessed 43 days later or at first sign of cachexia (Figure 1F). Tumors had to be resected from antibiotic-
treated animals sooner (2 days on average) than from control animals due to their increased rate of growth
(Figure 1G). Interestingly, the average number of metastatic lesions per animal was unchanged (Figure 1H),
but the overall metastatic burden was greater in the lungs from antibiotic-treated animals due to a larger
overall area occupied by lesions (Figure 1I). Thus, it is likely that while metastatic dissemination is not
increased following disruption of gut homeostasis, the progression of metastatic burden is accelerated
in antibiotic-treated animals similarly to primary tumor growth. Thus, we focused our attention on trying
to understand what is driving the enhanced primary tumor growth that accompanies a perturbed
microbiota.
VNMAA treatment severely disrupts the gut microbiota landscape
Using germ-free mice, which lack any microbiota, we sought to determine whether the increased tumor growth
was the direct result of VNMAA administration or the resulting perturbation of the gutmicrobiota.We observed
that tumor growth was not influenced by the administration of VNMAA in germ-free animals (Figure 2A). While
this alludes to the importance of the microbiota in regulating tumor progression, it does not indicate if the
observed elevated tumor growth observed in VNMAA-treated specific pathogen-free animals is the result of
losing beneficial microbial members or the outgrowth of an antibiotic-resistant pathobiont(s).
As expected, in VNMAA-treated- mice we observed a severe knockdown of the microbiota; relative abun-
dance of most bacterial phyla was dramatically reduced, but viruses and fungi did persist or overgrow (Fig-
ures 2B and S1C).
Concurrently, we also determined the metabolic milieu of the microbiota by performing 1H NMR on caecal
extracts. Unbiased principle component analysis (PCA) indicated differences in the VNMAA-treated ani-
mals when compared to control animals (Figure S1D). Further exploration of metabolites revealed that
of the 96 metabolites detected, 63 were significantly different between the two groups: 21 were elevated
while 42 were depleted after VNMAA treatment (Figure 2C). A number of amino acids were significantly
increased in the antibiotic-treated animals, in addition to fermentation substrates such as raffinose.
Conversely, SCFAs such as butyrate, acetate, and propionate and some of their conjugates (e.g. 2-meth-
ylbutryate), as well as the medium chain fatty acid caprylate, were significantly decreased after VNMAA
administration. This metabolic profile further demonstrates the degree of perturbation and loss of function
achieved through the VNMAA treatment as bacterial substrates (amino acids and polysaccharides) remain
unprocessed in the gut while bacterial metabolites are extremely sparse.
Although we maintained antibiotic administration throughout the experimental time course and observed
marked microbiota depletion in our VNMAA-treated animals, there may be still overgrowth of resistant
pathobionts which act to promote disease progression, as has been previously described in other BrCa
studies (Parhi et al., 2020; Rao et al., 2006). However, there is also evidence suggesting that bacterial spe-
cies can improve anti-BrCa tumor immune responses (Lakritz et al., 2014). We subsequently conducted a
passive fecal microbiota transfer (pFMT) experiment in which animals were exposed to fecal pellets present
in bedding from the alternate treatment group. This was designed to homogenize the microbiota between
experimental groups (i.e., resolve microbiota drifts due to experimental treatments) (McCafferty et al.,
2013; McCoy et al., 2017). As before, VNMAA treatment was started 5 days prior to PyMT-BO1 tumor
cell injection. From the point of orthotopic tumor induction, bedding was swapped from animals on the
alternate treatment (i.e. VNMAA-treated animals received bedding from the control group and vice versa).
These swaps were conducted every other day until the point of tumor harvest (see schematic, Figure 2D).
Exposure to VNMAA-treated feces did not increase tumor volumes in the control-treated pFMT animals
suggesting that a pathobiont is not responsible for accelerated tumor growth in VNMAA-treated animals.
However, regular pFMT with feces from animals with a normal microbiota led to a significant reduction in
Figure 1. Continued
(H) Bar plot (mean G s.e.m.) showing number of metastases in lungs of control and VNMAA-treated animals at
experimental endpoint.
(I) Bar plot (mean G s.e.m.) showing percent metastatic area in lungs of control and VNMAA-treated animals at
experimental endpoint.
See also Figure S1.
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VNMAA-treated tumor volumes (Figure 2E), intimating that enhanced tumor progression is being driven by
the loss of ‘‘protective’’ microbiota member(s).
Antibiotic-induced microbiota changes do not dramatically alter the tumor immune
microenvironment
Prior to further profiling studies, we decided to assess tumor growth over time with PyMT-BO1 cells, given
the dramatic differences observed in tumor sizes between antibiotic-treated and control animals at day 18
Figure 2. VNMAA administration reduces bacterial diversity and alters metabolic profiles in the gut
(A) Bar plot (mean G s.e.m.) showing endpoint tumor volumes of PyMT-BO1 tumors grown in germ-free animals subject
to VNMAA treatment (N = 1).
(B) Pie charts of shotgun metagenomics data (N = 2) showing the mean phyla-level relative abundances in caecal samples
from untreated (left) (n = 3), (middle) (n = 9) control, and VNMAA- (right) (n = 6) treated animals. Untreated samples were
obtained from non-tumor bearing animals.
(C) Filtered heatmap showing significantly regulated metabolites in caecal extracts of control and VNMAA-treated
animals obtained through 1H NMR (n = 5 individuals per condition; q < 0.01, p < 0.0025). Color ratio shown according to
Log2 fold change.
(D) Schematic of PyMT-BO1 passive caecal microbiota transplant (pFMT) experiment; following tumor cell injections,
bedding and fecal pellets from cages not receiving bedding swaps were transferred to cages receiving the opposing
treatment to donor cage. This was performed every other day to the experimental endpoint.
(E) Bar plot (mean G s.e.m.) showing endpoint tumor volumes from pFMT experiment (N = 1).
See also Figure S1.
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(Figure 1C). External measurements via calipers did not indicate any difference in tumor size at onset of first
palpable mass (day 7), but at each subsequent day of assessment, tumors were significantly larger in anti-
biotic-treated animals (not shown). However, due to the invasive nature of PyMT-BO1 tumor growth (e.g.
extensive peritoneal adhesions which were not apparent before excision), we noted a marked difference in
overall size between external caliper measurements and those taken after excision. Therefore, we per-
formed terminal experiments at various time points in order to more accurately assess differences in pri-
mary tumor growth. At all time points examined, tumor volumes were significantly larger in animals with
VNMAA-induced microbiota disturbances than those in control animals (Figure 3A). Thus, to ensure tumor
size was not a major confounder in our subsequent analyses, we decided to use 15 days of tumor growth:
this time point provides a balance between having sufficient material for multiple avenues of investigation
with minimal differences in tumor volumes between treatment groups.
Figure 3. Immune cell populations are not altered by VNMAA administration
(A) Graph of mean (Gs.e.m.) PyMT-BO1 endpoint tumor volumes at various time points: day 10 (N = 3; nR 20 animals per
condition), day 12 (N = 1; n = 14 animals per condition), day 14/15 (N = 4; nR 19 animals per condition), and day 18 (N = 3;
n = 21 animals per condition) after orthotopic injection showing growth kinetics of the model in mice undergoing either
VNMAA or control treatments.
(B and C) Bar plots showingmean (Gs.e.m.) percentages of (B) myeloid and (C) lymphoid tumor-infiltrating populations as
determined by flow cytometry.
(D) Intra-tumoral and (E) colon-derived cytokine levels (mean G s.e.m.) quantified by MSD V-plex assay (B–E, graphs are
representative of 3 independent experiments, n = 3–5 animals per condition per experiment). MØ = macrophage. See
also Figures S2 and S3.
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Figure 4. Intratumoral gene regulation is significantly different after VNMAA treatment, particularly in
metabolic processes
(A) Volcano plot describing the parameters used for differential expression, FDR-adjusted p value < 0.05 (Log10 adjusted)
and fold change >2 (Log2 adjusted). The top 7 DEGs are annotated on the graph.
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Broad-level immune cell phenotyping was performed on PyMT-BO1 tumors using flow cytometry to probe
previously published links between gut microbiota-derived metabolites and the immune system (Correa-
Oliveira et al., 2016). When profiling intra-tumoral CD11b+ myeloid cells and proportions of F4/80+ macro-
phages and Ly6G+ granulocytes (see Figure S2A for gating strategies), we did not observe any significant
changes (Figure 3B). The polarization state of tumor-associated macrophages (TAMs), using MHCII and
CD206 as markers, also did not reveal any significant differences in frequency of intra-tumoral leukocytes
(Figure 3B) or in the ratio of differentially polarized macrophages between treatments (Figure S2B). While
the proportion of immune cells in the tumor was overwhelmingly weighted toward myeloid cells (90–95% of
all CD45+ events), we also profiled T-cell populations: CD3+CD4+, CD3+CD8+, and T regulatory (Treg) cells
(CD4+FoxP3+). This analysis was also performed in spleen and mesenteric lymph node as a measure of pe-
ripheral immune cell populations. However, no changes were observed in the tumor (Figure 3C) or in either
organ (Figures S2C and S2D). Intra-tumoral cytokine analysis also indicated no significant changes (Fig-
ure 3D). Conversely, cytokine analysis of colon tissue revealed that multiple cytokines were significantly
reduced by VNMAA treatment, including CXCL-1, IL-1b, IL-2, and TNF-a (Figure 3E).
Broad-level immune cell phenotyping was also performed on EO771 and BRPKp110 tumors. Similarly to
findings in PyMT-BO1 tumors, we observed no significant differences in infiltrating myeloid or lymphoid
populations in these BrCa subtypes (Figure S3A).
Transcriptomic analysis of whole tumor RNA reveals a gene expression pattern consistent
with changes to metabolic processes
The lack of any observed changes at a gross immunological level suggested that other more specific im-
mune mechanisms may be contributing to the antibiotic-induced phenotype or other signaling pathways
in the tumor microenvironment might be driving accelerated tumor growth in VNMAA-treated animals. To
address these questions, we undertook global transcriptomic sequencing and analysis of whole tumors
which yielded a total of 172 differentially expressed genes (DEGs): 85 upregulated and 87 downregulated
in the tumors from VNMAA-treated animals (Figure 4A). To our suprise, functional clustering (using NIH
DAVID) indicated no differential regulation of immune-related pathways. However, a high frequency of
processes involved in cellular metabolism was identified. In total, 91 of 172 DEGs were associated with
metabolic transduction, transcription, migration, and differentiation (Figure 4B). More detailed GO defini-
tions indicated significant changes in lipid metabolism, gluconeogenesis, and protein metabolism. Further
analysis of these biological functions revealed two major groups of genes: genes such as ACACB, LPL, and
ACSL1, belonging to lipid metabolism, were upregulated in samples from VNMAA-treated mice; several
other genes, such as FBXL5, MADD, OAZ2, and TIPARP, relating to protein modification or metabolism,
were downregulated in samples from VNMAA-treated animals (Figure 4C).
Single-cell RNAseq of tumors from VNMAA-treated animals reveals changes in stromal cell
populations
Although antibiotic-induced changes in the gut microbiota may drive changes in metabolic pathways used
by PyMT-BO1 tumors to accelerate primary growth, we conjectured these differences were likely conse-
quential of alterations in tumor progression, rather than direct drivers. The lack of any observed alteration
in the ‘‘classical’’ tumor immune microenvironment in VNMAA-treated animals, particularly given the
known association between TAMs and PyMT mouse models (Qian and Pollard, 2010), and the study
from Buchta Rosean et al. demonstrating antibiotic-induced alterations in macrophage recruitment to
luminal A mouse models of BrCa (Buchta Rosean et al., 2019) suggested either functional differences within
populations and/or changes in other atypical or rare immune populations in tumors from VNMAA-treated
mice. To capture possible differences in cell-type behavior between treatments, we profiled the tumor
microenvironment at single cell (sc) resolution using day 13 samples to test for early potential immune-
mediated changes. Uniform Manifold Approximation and Projection (UMAP) analysis (Becht et al., 2018)
revealed 21 clusters, representing both tumor cells and cells of the tumor microenvironment (Figure 5A).
Some of these clusters represented tumor infiltrating immune cells including macrophages, B cells, and
T cells.
Figure 4. Continued
(B) High-level analysis of biological process enrichment using DAVID, separated by over-arching biological function.
(C) Heatmaps showing specific genes which are related to lipid (left) and protein (right) metabolism from our DEG set.
Color ratio is shown according to Log2 fold change.
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While the overall number of cells in most identified clusters was broadly similar between each treatment,
UMAP clustering revealed two clear differences in tumors from VNMAA-treated animals compared to con-
trols: reduced B-cell numbers and increased cells within one of two stromal populations (Figures 5A and
5B). B cells can play anti-tumorigenic roles in some settings (Carmi et al., 2015; DiLillo et al., 2010; Tao
et al., 2015). However, after applying the same gene signatures used to define clusters in the scRNAseq
to our deconvoluted bulk RNAseq data on day 15, we observed no obvious differences in percentages
of B-cell signatures between conditions (Figure 5C). This further correlated with additional flow cytometric
analyses, showing no differences between control and VNMAA-treated tumors with respect to B-cell
numbers at day 15 (Figure S3B). In support of these findings, this immune population is not generally
Figure 5. VNMAA treatment alters cellular profile of the tumor microenvironment
(A) UMAP clustering of cell types identified through single-cell RNAseq of tumors from control (left) and VNMAA (right)-
treated animals. Pooled data from 2 animals per condition. Yellow circles denote B-cell populations; purple circles denote
a stromal cell cluster.
(B) Percent abundance of cell types relative to the total number of cells per treatment group sequenced through single-
cell RNAseq (pooled data from 2 samples per treatment).
(C) Percent abundance of cell types relative to the total number of cells per sample following deconvolution of bulk
RNAseq presented in Figure 4 (n = 3 samples per condition). See also Figure S4.
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Figure 6. Clinically relevant antibiotic, cephalexin, accelerates tumor growth
(A) Schematic of PyMT-BO1 experimental timeline; cephalexin was administered on Monday, Wednesday, and Friday for
the duration of the experiment until cessation 15 days after orthotopic injection.
(B) Bar plot of mean (Gs.e.m.) endpoint tumor volumes from cephalexin-treated versus water-treated animals (N = 3).
(C) Bar plots show mean (Gs.e.m.) percentages of viable cells of myeloid (top) and lymphoid (bottom) tumor-infiltrating
populations as determined by flow cytometry (representative of 3 independent experiments).
(D) Pie charts of shotgun metagenomics data (N = 2) showing the mean phyla-level relative abundances in caecal samples
from control (left) (n = 9) and cephalexin (right) (n = 6)-treated animals.
(E) Filtered heatmap showing hierarchal clustering of bacterial species with significantly different relative abundances
following a two-group comparison of both antibiotic treatments versus control samples (p = 0.001, q < 0.05) (top); and a
filtered heatmap showing hierarchal clustering of bacterial species relative abundances following a two-group
comparison of both antibiotic treatments versus control samples with relaxed statistical parameters (p < 0.05, q = 2.085)
(bottom); relative abundances were determined by shotgun metagenomics of caecal contents (n R 6 individuals per
condition); color ratio shown according to Log2 fold change.
(F) Box and whisker plot (left) showing significantly reduced relative abundances of Faecalibaculum rodentium
(F. rodentium) in both VNMAA and cephalexin-treated samples (N = 2) and a bar graph (right) of PyMT-BO1 tumor
volumes at experimental endpoint (day 15). Experimental setup as in (A). Control animals (yellow bar) were gavaged three
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considered a major player in the MMTV-PyMT tumor model (DeNardo et al., 2009). We, therefore, decided
to focus our attention on the stromal cell cluster. Both scRNAseq (Figures 5A and 5B) and deconvoluted
bulk RNAseq (Figure 5C) suggested this stromal cluster was increased in cell numbers in tumors from
VNMAA-treated mice. Closer examination of the gene signature of this cluster identified a number of
collagen transcripts (Figure S4A). Given the known links between collagen, fibrosis, and BrCa progression
(Boyd et al., 2007; Huo et al., 2018) and recent work showing fibrosis is increased in response to antibiotic-
inducedmicrobiota perturbations in the luminal Amodel (Buchta Rosean et al., 2019), we hypothesized that
this may also be the case in our luminal B model. However, Picro-Sirius Red staining (which demarcates
collagen fibers) of tumor sections from control and VNMAA-treated animals did not show any obvious dif-
ferences in stromal collagen deposition when comparing the two conditions (Figure S4B).
Clinically relevant antibiotics induce similar phenotypic changes in primary tumor growth and
tumor immune cell infiltration
VNMAA treatment allowed us to establish a link between microbiota homeostasis and tumor growth ki-
netics, but the induced disturbances are severe, with loss of many bacterial species (Figure 2A) and large
shifts in gut metabolite profiles (Figure 2B). We therefore investigated the effects of a more clinically rele-
vant antibiotic in our PyMT-BO1 model. After discussing prevalent antibiotic usage with our clinical col-
leagues (US and UK), we decided to perturb themicrobiota with cephalexin, a broad-spectrum beta-lactam
antibiotic that targets gram-positive bacteria (Bush and Bradford, 2016). Using an administration protocol
identical to that of VNMAA (Figure 6A), mice were gavaged with patient-relevant doses of cephalexin
(35 mg/kg in humans) (thrice weekly), starting 5 days prior to orthotopic injection of PyMT-BO1 cells until
tumor harvest (day 15). Primary tumor growth was significantly accelerated in cephalexin-treated animals
(Figure 6B). A similar change in tumor growth kinetics led us to compare the two different antibiotic treat-
ments relative to control cohorts, and as observed in VNMAA-treated animals, we saw no gross changes in
tumor infiltrating myeloid or lymphoid cell populations by flow cytometry (Figure 6C).
As expected, the microbiota changes induced by cephalexin were much less drastic than those resulting
from VNMAA administration with only a few taxa increasing and decreasing relative to control (Figures
6D and S1C). Given we hypothesize accelerated tumor growth is driven by the loss of tumor protective mi-
crobiota members, we analyzed caecal samples from control, VNMAA, and cephalexin-treated animals us-
ing whole genome shotgun sequencing to understand the effect on bacterial abundances at a species
level. Given the VNMAA cocktail ablated the bacterial element of the microbiota almost entirely, alongside
our hypotheses of a loss of an anti-tumorigenic microbiota member(s), we performed unsupervised clus-
tering via a two-group comparison (control versus both antibiotic-treated samples), with a false discovery
rate (FDR) correction set to q < 0.05, to identify species which were reduced similarly in both antibiotic
groups. This analysis suggested the common loss of only 2 of 52 assigned bacterial species (Enterorhabdus
caecimuris and Anaerotruncus sp. G3_2012) between the two different antibiotic regimens, neither of
which have been particularly associated with cancer (Figure 6E top). However, when relaxing the FDR pa-
rameters and filtering for species with an uncorrected p value of p < 0.05, we identified 11 which were
reduced in both cephalexin and VNMAA samples relative to control (Figure 6E bottom). Of these, several
have already been associated with immune regulatory and anti-tumorigenic roles. Of immediate interest
was the reduction of Faecalibculum rodentium, which was recently observed to have a protective role in
an ApcMin/+ spontaneous mouse model of colorectal cancer, as well as in wild-type C57BL/6 mice induced
with colorectal cancer through administration of azoxymethane and dextran sulfate sodium (Zagato et al.,
2020). A targeted Wilcoxon test of F. rodentium abundances in cephalexin and VNMAA compared to con-
trol samples confirmed it was significantly reduced in both VNMAA- and cephalexin-treated samples (Fig-
ure 6F, left). Subsequently, we tested whether supplementation with F. rodentium would rescue the
enhanced tumor growth induced by antibiotics. Using the previously described antibiotic treatment regi-
mens (see schematics Figures 1A and 6A), animals were treated with vehicle (control) or VNMAA thrice
weekly to point of a palpable tumor; at this point, control animals continued to receive vehicle only, while
Figure 6. Continued
times per week (Monday, Wednesday, Friday) to point of tissue harvest. VNMAA animals were gavaged with
antibiotics (every Monday, Wednesday, Friday) to the point of a palpable tumor (day 7 post orthotopic injection), at
which point they were switched to either water (purple bar) or to F. rodentium (purple stippled bar).
(G) Bubble plot showing metagenomic changes in relative abundance of several bacterial species in caecal samples at
experimental endpoint following treatment regimens as described. See also Figures S5 and S6.
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half of the VNMAA animals were shifted to vehicle treatment (VNMAA to control), and the other half were
treated with F. rodentium (VNMAA to F. rodentium). These treatments continued thrice weekly to the point
of tissue harvest (day 15). VNMAA to control animals showed accelerated tumor growth, but we observed
reduced tumor growth in VNMAA to F. rodentium treated animals (Figure 6F, right), suggesting this spe-
cies may contribute to a protective role of the microbiota in regulating BrCa. Shotgun metagenomics of
caecal contents confirmed the loss of F. rodentium in VNMAA to control animals and its return in VNMAA
to F. rodentium animals (Figure 6G).
Previous metabolic analysis of VNMAA caecal samples compared to controls had shown a significant inhi-
bition of gut function based on the inverse abundances of high levels of bacterial substrates but reduced
metabolites. However, as metagenomic analysis highlighted a markedly reduced alteration in bacterial di-
versity following cephalexin treatment compared to VNMAA, we sought to identify whether there was any
obvious change in metabolite abundance which may be associated with tumorigenic influence in the
breast. While there was some variability between the samples from cephalexin-treated animals, the profiles
generally had more in common with samples from the control cohort than they did with the VNMAA group.
However, similarly to VNMAA samples, several amnio acids (leucine, isoleucine, valine, and tryptophan)
were increased. To our surprise, there were far fewer similar comparisons for bacterial-derivedmetabolites,
such as the SCFAs butyrate, acetate, and propionate, though levels of the medium chain fatty acid capry-
late were generally repressed (Figure S5). However, multiple t-tests with a corrected Q statistic identified
only adenosine monophosphate as being significantly reduced in cephalexin samples versus control (p =
0.000447, q = 0.05). In an attempt to link the cephalexin-induced changes in gut taxonomic profiles and
metabolism with the observed increase in tumor growth, a functional analysis using confint() from the
coin package was performed on the shotgun metagenomics data to identify possible bacterial pathways
which may be linked to disease progression. However, of the 93 pathways which were identified, only six
were significantly different in their ‘‘abundance’’ relative to controls. Three were increased while the other
three were decreased in their activity in samples from cephalexin-treated animals (Figure S6). Of those
pathways identified as significantly changed, only the Bifidobacterium shunt, depressed in cephalexin-
treated animals, suggested any potential link to SCFA production. Despite this, SCFAmetabolites (e.g. ac-
etate and propionate) were not significantly altered in this group of animals.
Antibiotic-induced stromal mast cells accelerate tumor growth
Given the accelerated tumor growth that occurs in both VNMAA- and cephalexin-treated animals, it is
intriguing to speculate a common driver associated with these responses. Although our previous analyses
did not indicate any obvious ‘‘candidates’’, including immune populations, closer examination of the tran-
script profile of the stromal cell cluster (from our scRNAseq analysis) indicated the presence of a number of
transcripts expressed bymast cells (e.g.Mcpt1, Mcpt8, and Cma1). Moreover, while we did not observe any
gross differences in tumor fibrosis when comparing tumors from control and VNMAA-treated mice, exam-
ination of Picro-Sirius Red-stained tumor sections from VNMAA-treated samples at higher magnification
indicated a number of granular cells predominantly situated in tumoural stroma which were reminiscent
of mast cells. Toluidine Blue staining of tumor sections confirmed their identity as mast cells (Figure 7A).
Importantly, quantitation of mast cells showed increased stomal numbers in sections from VNMAA-treated
mice, particularly in the extra-tumoral stroma (Figure 7B). Moreover, while we did not observe statistically
significant changes in mast cell numbers in tumors harvested from our F. rodentium studies, there were
generally reduced numbers of mast cells in VNMAA to F. rodentium treated animals compared to VNMAA
to control animals (Figure 7C). Given our speculation of a common mechanism driving accelerated primary
tumor growth following antibiotic-induced microbiota perturbations, we also enumerated mast cell
numbers in EO771 tumors from VNMAA-treated animals and in PyMT-BO1 tumors from cephalexin-treated
animals; both showed significantly increased mast cell numbers in the tumor stroma of antibiotic-treated
mice compared to controls (Figures 7D and 7E, respectively). We observed similar findings in the BRPKp110
luminal A tumor model from animals treated with vancomycin, neomycin, metronidazole, gentamicin, and
ampicillin (VNMGA) (Figure 7F) and in a Her2-neu spontaneous model in animals treated with vancomycin
only (Figure 7G).
Collectively, these observations prompted us to question whether this, previously overlooked, population
of myeloid-derived immune cells was responsible for accelerated primary tumor growth in antibiotic-
treated animals. In an attempt to determine whether targeting mast cell function influences tumor growth,
we treated both control and VNMAA-treated mice with cromolyn, a mast cell stabilizer which prevents
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Figure 7. Increase in stroma associated mast cells promotes tumor growth following VNMAA treatment
(A) Histological staining for collagen deposition (Picro-Sirius Red), mast cells (toluidine blue), and their co-localization
(overlay) in a representative image of a tumor from a VNMAA-treated animal. Arrows point to mast cells. Scale bar
represents 100 mm.
(B) Bar and whisker plot of mast cell density (mast cells/mm2) in PyMT-BO1 tumors from control and VNMAA-treated
animals (left) and toluidine blue-stained MCs present in peripheral tumor stroma (dotted line denotes tumor margin;
arrows point to mast cells; scale bar reprsents 50 mm. N = 2; n R 13 animals per condition).
(C) Mast cell counts in F. rodentium study.
(D) Bar and whisker plot of mast cell density in EO771 tumors from control and VNMAA-treated animals (N = 2; n R 7
animals per condition).
(E) Bar and whisker plot of mast cell density in PyMT-BO1 tumors from control and cephalexin-treated animals (N = 1; nR
5 animals per condition).
(F) Bar and whisker plot of mast cell density in BRPKp110 tumors from control and VNMGA-treated animals (N = 1; n = 5
animals per condition).
(G) Bar and whisker plot of mast cell density in d16HER2 tumors from control and vancomycin-treated animals (N = 1; n = 4
animals per condition).
(H) Schematic of experimental timeline for mast cell inhibition experiment using cromolyn administered over the last
5 days of the experiment.
(I) Bar plot of mean (Gs.e.m.) endpoint tumor volumes of cromolyn-treated animals with either water or VNMAA versus
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degranulation (Zhang et al., 2016) (see Figure 7H for experimental regimen). During the final 5 days of tu-
mor growth, mice were treated with either cromolyn (10 mg/kg, delivered i.p.) or normal saline as a vehicle
control. As expected, tumors were significantly larger in VNMAA-treated animals when compared to con-
trol animals. Notably, cromolyn inhibited tumor growth in antibiotic treated animals but had no influence
on control animals (Figure 7I). These data suggest a potential role for mast cells in BrCa progression in an-
imals with an antibiotic-induced disturbed microbiota.
DISCUSSION
The use of antibiotics is widespread among patients with cancer to prevent opportunistic infection, both
prophylactically prior to surgery and during periods of immune compromisation. However, the rising threat
of antibiotic-resistant pathogens highlights the importance of re-evaluating antibiotic use in the clinic.
Antibiotic-resistant infections kill hundreds of thousands of people per year worldwide, and this figure is
expected to grow exponentially over the next 30 years (Mullard, 2016). Moreover, some evidence suggests
that antibiotic use may not be beneficial to all patients. Recent studies have demonstrated an unequivocal
role of the patient microbiome in orchestrating anti-tumor responses, and many have found that the use of
antibiotics compromises treatment efficacy in several cancers (Velicer et al., 2004, 2006). It is therefore pru-
dent that clinicians begin to carefully consider the efficacy of antibiotic use in their patients. To do so, we
must fully understand how the microbiota impact different cancer pathologies. Other groups have made
progress in understanding how antibiotics affect immunogenic cancers (Gopalakrishnan et al., 2018; Mat-
son et al., 2018; Routy et al., 2018; Vetizou et al., 2015); however, to date, only a small number of studies
have looked at their effects on BrCa (Buchta Rosean et al., 2019; Rossini et al., 2006; Teng et al., 2021).
Using clinically relevant BrCa models, we set out to understand whether the use of antibiotics has any
impact on tumor progression. In luminal B (PyMT-BO1), basal-like (EO771), and luminal A (BRPKp110)
BrCa tumormodels, a prolonged disruption of the gut microbiota via antibiotic treatment resulted in accel-
erated tumor growth. This suggests that antibiotic treatment is detrimental across multiple BrCa intrinsic
subtypes. In addition to those described in this paper, Buchta Rosean et al. (2019) employed antibiotic
treatment which incorporated a 4-day recolonization period following a two-week antibiotic administration
prior to tumor induction and observed increased metastasis to the lungs in the BRPKp110 luminal A BrCa
model. Together, these results support the hypothesis that antibiotics negatively impact the microbiota
which in turn negatively impacts the disease outcome of BrCa.
Use of antibiotics has been shown to impact tumor growth in both pre-clinical and human studies. Howev-
er, these studies largely focus on the influence of the microbiota on anti-tumor therapies. For example,
Vetizou et al. and Routy et al. probed the impact of antibiotics on anti-CTLA4 and anti-PD-1 therapies,
respectively, finding that these treatments are rendered ineffective when the microbiota is depleted (Routy
et al., 2018; Vetizou et al., 2015). However, when comparing control and antibiotic-treated animals without
administration of anti-tumor agents, these groups found no difference in tumor volume. This suggests that
our findings may be specific to BrCa subtypes and are supported by Rossini et al., who in 2006 demon-
strated, using HER2/neu transgenic mice, that antibiotic administration alone increased the incidence of
spontaneous BrCa (Rossini et al., 2006).
Importantly, we show that an antibiotic that is used widely in patients with BrCa (cephalexin) accelerates the
progression of BrCa in the PyMT-BO1 model. This is a particularly intriguing observation as it suggests that
even relatively small deviations from microbiota homeostasis can negatively impact BrCa progression. To
date, there have been no human studies linking microbiota disruptions causatively to BrCa progression.
However, several human studies have described a loss of gut microbial diversity in patients with BrCa
compared to normal control subjects (Goedert et al., 2015; Guan et al., 2020; Wu et al., 2020; Zhu et al.,
2018). Thus, our observations intimate that, in these studies, the microbiota may be influencing BrCa pro-
gression rather than changing as a consequence of it.
Given the results of our passive FMT study (Figure 2E), we hypothesize that a loss of mutualistic microbiota
members is responsible for the accelerated progression (rather than the amplification of a pathobiont). A
direct comparison of the microbiota profiles between VNMAA-treated and cephalexin-treated animals
(compared to controls) showed reduced relative abundance of Lactbacillus reuteri, Lachnospiraceae bac-
terium, and F. rodentium, among others. Many of these species are postulated to play anti-tumorigenic
roles in a number of different cancers (Rasouli et al., 2017; Viaud et al., 2013; Zagato et al., 2020).
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F. rodentium was particularly interesting to us, given its recently proven role in limiting the development of
colorectal cancer in mouse models (Zagato et al., 2020). Based on the evidence from the pFMT study
suggesting the driver for tumor progression was likely the loss of commensal bacterial species, we supple-
mented antibiotic-treated animals with F. rodentium and observed a significant reduction in tumor vol-
umes versus ‘‘control supplemented’’ animals. However, several ‘‘probiotic’’ studies have described
improved efficacy when using a cocktail of microbes, often from several genera. For example, Tanoue
et al. (Tanoue et al., 2019) demonstrated that administration of an 11-strain commensal cocktail, isolated
from human fecal samples and associated with improved CD8 T cell activity, to germ-free mice with en-
grafted MC38 adenocarcinoma tumors resulted in improved anti-tumor responses during anti-PD-1 check-
point inhibitor therapy. Additionally, the commercial probiotic VSL#3, which comprises a combination of
Bifidobacteria, Lactobacillus, and Streptococcus species, has been shown to prevent colitis-associated
colorectal cancer in rats (Appleyard et al., 2011). We have yet to test the other commonly reduced species
in this way, but it is possible that a cocktail of these commensals may improve anti-tumor rescue effects
further. Noteworthy, however, is the observation that some of the identified potentially beneficial species
supressed by VNMAA treatment (L. reuteri and many of the L. bacterium species, for example) return after
antibiotic treatment is halted (e.g. in VNMAA to control animals – Figure 6G). Without the addition of
F. rodentium, the repopulation of the microbiota by these species does not appear to reduce tumor
growth, at least within the timescale of the experiments. This suggests that either F. rodentium is playing
a key anti-tumorigenic role or its presence within a complex ‘‘cocktail’’ of beneficial commensals is impor-
tant; we cannot currently rule out either possibility.
While NMR analysis clearly demonstrated a dramatic loss of microbial-derived metabolites (e.g. SCFAs), in
the VNMAA-treated animals, there were far fewer differences in the cephalexin samples, which correlates
with the more subtle microbial taxa changes using a single vs. a cocktail antibiotic regimen. Of those me-
tabolites profiled in cephalexin-treated animals, it is unlikely that any of these are solely responsible for
driving increased tumor growth. In the absence of clear metabolic differences as well as any gross changes
in canonical pro- or anti-tumorigenic immune populations in our models, we decided to employ RNA
sequencing of whole tumor extracts to gain further mechanistic insight and/or perhaps uncover alterations
in immune activation pathways (as opposed to overall cell numbers) that might explain accelerated tumor
progression in antibiotic-treated mice. Here too, however, we did not detect any differences in immune
signatures between control and antibiotic-treated animals. Rather, biological process enrichment analysis
showed that alterations were predominantly seen in metabolic processes, particularly in lipid and protein
metabolism. Metabolic reprogramming is a well-established hallmark of cancer, and upregulation of lipid
metabolism is strongly associated with tumorigenesis, particularly in BrCa (Benito et al., 2017; Naeini et al.,
2019; Zhang et al., 2019). In addition to changes in lipid metabolism, several genes associated with protein
metabolism were downregulated by VNMAA treatment, and many of these genes are known tumor sup-
pressors. While these findings provide therapeutic avenues to explore for combating the deleterious ef-
fects of antibiotic use, we felt they were more likely a readout of accelerated disease progression, rather
than a direct consequence of microbiota perturbation.
As mentioned above, Buchta Rosean et al. (2019) demonstrated striking findings using the BRPKp110
luminal A model with a similar antibiotic cocktail. They observed that microbiota disruption resulted in
enhanced metastatic dissemination as well as the establishment of a tumor microenvironment that favors
elevated macrophage infiltration and increased tumor fibrosis. Therefore, we decided to probe immune
signatures in more detail, via in-depth scRNAseq analyses of control and VNMAA-treated tumors.
Although we observed a reduction in B-cell profiles in antibiotic treated tumors (Figure 6), flow cytometry
studies (at a later time point) and deconvolution of the bulk RNA-sequencing data did not reveal any dif-
ferences in this immune population. Therefore, although it may be speculated that in the PyMT-BO1 BrCa
model B cells play an (early) anti-tumorigenic role, further studies are required to probe this in more detail.
Notably, previous studies have indicated B cells can both promote and inhibit cancer progression (Yuen
et al., 2016), and mice specifically lacking B cells were unaffected in terms of tumor latency or progression
in the MMTV-PyMT model (DeNardo et al., 2009), highlighting the complexity and dynamic nature of spe-
cific immune cell populations in cancer models.
A further immune-linked signature that was observed with scRNAseq was an increased stromal profile in
tumors from VNMAA-treated mice. This initial finding and subsequent histological analysis revealed an in-
crease in a discreet immune cell population in tumors from antibiotic-treated mice; antibiotic-induced
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microbiota perturbations increased mast cell numbers in tumor stroma and when functionally blocked (i.e.
blocking granule release), tumor growth was reduced, highlighting that this cell type is likely a key driver of
accelerated tumor growth after antibiotic-induced microbiota perturbations (Figure 7). As with most im-
mune cells, mast cells have been shown to play both anti- and pro-tumourigenic roles in multiple cancers
(Varricchi et al., 2017) including BrCa (Aponte-Lopez et al., 2018). He et al. showed that whenmast cell-defi-
cient mice (KitW-sh/W-sh) are crossed with MMTV-PyMT mice, tumor growth and metastatic potential are
significantly curtailed (He et al., 2016). Importantly, the data presented suggest that microbiota distur-
bances increase mast cell homing to tumors and/or their increased proliferation within tumors. This corre-
lation holds true in every subtype of BrCa we have so far examined, suggesting a universal mechanism
driving the response. However, as mast cell inhibition of control animals had little impact on tumor progres-
sion, it is likely there is differential regulation of their pro-tumorigenic function specifically by the micro-
biota. There is precedent in the literature to suggest an interplay between the gut microbiota and mast
cell function: germ-free mice exhibit mast cells with impaired functionality (Schwarzer et al., 2019), and mul-
tiple interactions between mast cells and microbiota members are known to regulate mast cell activation
(De Zuani et al., 2018), though these studies are largely restricted to mucosal mast cells. Intriguingly, both
SCFAs and amino acids are capable of regulating mast cell function (Lechowski et al., 2013; Wang et al.,
2018).
In conclusion, our work has shown that disruption of the gut microbiota via antibiotics has detrimental im-
pacts on BrCa progression. We speculate that antibiotic-induced loss of a beneficial microbiota specie(s)
has the potential to release the ‘‘brakes’’ on tumor growth by re-programming mast cell homing and/or
function. Our future studies will focus on understanding from ‘‘where’’ increased mast cells are coming,
‘‘what’’ changes are occurring in mast cells in response to microbiota disruption, ‘‘who’’ is responsible
for inducing these changes, and ‘‘how’’ they promote them.
Limitations of study
As with most murine studies of the gut microbiota, there are some important limitations to note. Firstly, we
have employed broad-spectrum and systemically administered antibiotics, so we cannot entirely rule out
that microbiotas beyond the gut are contributing to observed phenotypes. However, we do feel this
concept is somewhat mitigated against by the F. rodentium studies in which microbiota supplementation
was applied directly to the gut; these studies demonstrate a return to normal tumor growth after
F. rodentium supplementation.
Secondly, due to the targeted nature of 1H NMR, it is possible that metabolites which were not included in
these analyses may be differentially abundant between treatment groups, particularly when comparing
samples from control versus cephalexin-treated animals. This may explain why no obvious links between
the pathways identified in the shotgun WGS dataset were linked with associated changes in metabolite
concentrations in caecal samples from cephalexin-treated animals. Interestingly, F. rodentium has been
linked to butyrate production, but butyrate levels did not change in response to cephalexin treatment.
Thirdly, while shotgun WGS approaches have significantly improved the depth at which the microbiota
composition can be described, there are still several areas where descriptive data are lacking. For example,
proportionally there are far more annotated genomes for bacterial organisms than there are for fungi and
viruses. Our data had many ‘‘unassigned’’ reads which are likely linked to undescribed organisms. It is
possible that these organisms may play a role in a perturbedmicrobiota which influences our BrCa models.
Fourthly, for our scRNAseq analyses, we employed 10X Genomics technology, which uses a short read plat-
form to identify cell types. While this was ideal for obtaining a broad overview of the cell types within the
tumor microenvironment, it likely curtailed our ability to detect differences in small populations of cells
(e.g. mast cells) or in specific biological processes. A longer read platform would improve both aspects.
Finally, our study employed the use of cromolyn sodium as a drug to inhibit mast cell function. However,
cromolyn does not specifically target mast cells alone. It has been associated with inhibitory effects on
other granulocytes, such as basophils (Mazurek et al., 1980). There is also some debate in the literature
as to whether cromolyn is effective at inhibiting mast cell degranulation in mice (Oka et al., 2012) and as
to whether it can elicit its effects over a short time course (Minutello and Gupta, 2021). As such, in order
to improve the translational relevance of these studies, it will be important in our future studies to validate
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the role of mast cells in mediating antibiotic-induced perturbations of the microbiota in BrCa by perform-
ing studies in mast cell-deficient mice (Dudeck et al., 2011; Feyerabend et al., 2011; Grimbaldeston et al.,
2005). Though in this regard, it is worth reiterating that mast cells have been shown to drive tumor growth
and metastases in the MMTV-PyMT BrCa model in KitW-sh/W-sh mice (He et al., 2016).
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REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
CD45_PerCP-Cy5.5 (clone 30-F11) eBioscience CAT #: 45-0451; RRID: AB_1107002, AB_10324454
CD3_APC (clone 145-2C11) eBioscience CAT #: 17-0031; RRID: AB_469315
CD4_PE (clone GK1.5) eBioscience CAT #: 12-0041; RRID: AB_465506
CD8_PE-Cy7 (clone 53-6.7) eBioscience CAT #: 561967; RRID: AB_10893346
FoxP3 _eFluor450 (clone FJK-165) eBioscience CAT #: 48-5773; RRID: AB_1518813
CD19_BV650 (clone 6D5) BioLegend CAT #: 115541; RRID: AB_11204087
CD11b_AlexaFluor 700 (clone M1/70) eBioscience CAT #: 56-0112-80; RRID: AB_657585
F4/80_PE-Cy5 (clone BM8) eBioscience CAT #: 15-4801; RRID: AB_468797
Ly6G_APC-Cy7 (clone IA8) BD CAT #: 560600; RRID: B_1727561
CD206_PE (clone C068C2) BioLegend CAT #: 141705; RRID: AB_10896421
MHCII_eFluor450 (clone M5/114.1.2) eBioscience CAT #: 48-5321-82; RRID: AB_1272204
Anti-Ki67 Abcam CAT #: ab15580; RRID: AB_443209
Anti-Endomucin (clone V.7C7) Santa Cruz CAT #: sc-65495; RRID: AB_2100037
Polyclonal Goat anti-Rabbit immunoglobulins/HRP Agilent CAT #: P0448, RRID:AB_2617138‘
Polyclonal Rabbit anti-Rat immunoglobulins/HRP Agilent CAT #: P0450, RRID:AB_2630354
Bacterial and virus strains
Faecalibaculum rodentium (Type strain 103405) DSMZ DSM 103405
Chemicals, peptides, and recombinant proteins
Amphotericin-B Merck Life Science CAT #: A2411
Ampicillin Merck Life Science CAT #: A9518
Vancomycin Hydrochloride Fisher Scientific CAT #: 11956911
Metronidazole Merck Life Science CAT #: M3761
Neomycin trisulfate salt hydrate Merck Life Science CAT #: N1876
Cephalexin Merck Life Science CAT #: C4895
Cromolyn Sodium Merck Life Science CAT#: C0399
Toluidine Blue-O Merck CAT #: 198161
Safranin-O Abcam CAT #: ab146329
Alcian Blue 8GX Merck Life Science CAT #: A3157
Harris Hematoxylin Soultion Merck Life Science CAT#: HHS128
Eosin Merck Life Science CAT#: HT110116
Critical commercial assays
MPBio FastDNA SPIN Kit for Soil MPBio CAT #: 116560200
Mesoscale Discovery V-PLEX Pro-inflammatory
Panel 1 Mouse Kit
MSD CAT #: K15048D
Foxp3/Transcription Factor Staining Buffer Kit eBioscience CAT #: 00-5523-00
Fetal bovine serum Gibco CAT #: 10500-064
Dulbecco’s Modified Eagle’s Medium - High Glucose Merck Life Science CAT #: D6429
Pen Strep Gibco CAT #: 15140-122
70mm Cell Strainer Corning Costar CAT#: 352350
Live/Dead_Green Thermofisher CAT #: L34970
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
Live/Dead_Red Thermofisher CAT #: L34971
Collagenase type IV Gibco CAT #: 17104-019
Hyaluronidase from sheep testes Merck Life Science CAT #: H6254
Deoxyribonuclease 1 from bovine pancreas Merck Life Science CAT #: D4263
Deposited data
Shotgun metagenomics files This manuscript ENA : PRJEB40951
Bulk RNA-seq files This manuscript ENA : PRJEB40951
scRNA-seq files This manuscript ENA : PRJEB40951
Experimental models: Cell lines
PyMT-BO1 cells From Katherine Weilbaecher (Su et al., 2016)
EO771 cells Kind gift from Jeffrey Pollard (Ewens et al., 2005)
BRPKp110 cells From Melanie Rutkowski (Buchta Rosean et al., 2019)
Experimental models: Organisms/strains




Delta16HER2 transgenic FVB mice (Marchini et al., 2011) N/A
Software and algorithms
GraphPad Prism 9 GraphPad Software 9.1.0
FlowJo FlowJo V10
Omics Explorer Qlucore 3.6
BBDuk sourceforge.net/projects/bbmap/ v.38.76
BBMap sourceforge.net/projects/bbmap/ v38.76
MetaPhlAn v3.0 (Segata et al., 2012) R package
ggplot2 Wickham, 2016 R package
FastQC (Andrews, 2010) 0.11.3
FASTX-Toolkit (Hannon, 2010) 0.1.5
Tophat (Kim et al., 2013) 2.1.1
Cufflinks (Trapnell et al., 2013) 2.1.0
Kallisto (Bray et al., 2016) R package
DeSeq2 (Love et al., 2014) R Package
Cell ranger v2.0 10X Genomics 2.0.0
Seurat V3.0 Stuart et al. 2019 R package
HUMAnN3 (Franzosa et al., 2018) v3.0.0.alpha
Kraken2 Wood et al., 2019 v2.1.0
Fastp Chen et al., 2018 v0.21.0
DIAMOND Buchfink et al., 2015 v0.9.24
R R Core Team 2013 v3.6.2
Coin (Hothorn et al., 2008) v1.4-1; R package
Stats R v3.6.2; R package
BioRender https://biorender.com/ Under individual license to lead
contact, Stephen Robinson
Other
Axio Imager M2 Zeiss N/A
LSRFortessa flowcytometer BD N/A
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Requests for further information, resources and reagents should be directed to and will be fulfilled by the
lead contact, Dr. Stephen Robinson, Gut Microbes and Health Program, Quadram Institute Bioscience,
Norwich Research Park, Norwich, UK, Stephen.Robinson@uea.ac.uk.
Material availability
This study has not generated new unique reagents.
Data and code availability
Shotgun metagenomic, Bulk RNA-seq and scRNA-seq data have been deposited at European Nucleotide
Archive (ENA) and are publicly available as of the date of publication. Accession numbers are listed in the
key resources table.
No original code was used in the analysis of data presented in this manuscript. All packages and pro-
grammes used for data analysis are listed in the key resources table.
EXPERIMENTAL MODELS AND SUBJECT DETAILS
Animals
All animals for orthotopic studies were female C57BL/6 mice and were sourced in-house. All animals were
age matched at 8–10 weeks old. All animal experiments were performed in accordance with UK Home Of-
fice regulations and the European Legal Framework for the Protection of Animals used for Scientific Pur-
poses (European Directive 86/609/EEC).
Animal experimentation
To minimize experimental bias, mice were pooled and randomly allocated to treatment groups at the start
of each experiment. Subsequently, animals from each treatment group (which generally required housing
across multiple cages) were pooled and randomly re-distributed at each gavage/additional treatment.
Wherever possible, experimental measurements (e.g. tumor volume measurements) were performed
blind.
VNMAA and cephalexin antibiotic administration
Animals were treated with antibiotics three times weekly by oral gavage (200mL in water). Animals were
treated with either a cocktail consisting of 0.2 mg/ml Amphoteracin B (Merck Life Science, Gillingham,
UK), 5 mg/ml Vancomycin (Merck Life Science), 10 mg/ml Neomycin (Merck Life Science), 10 mg/ml Metro-
nidazole (Merck Life Science) with drinking water being supplemented with 1 mg/ml Ampicillin (Merck Life
Science) or 43.2 mg/ml Cephalexin (Merck Life Science). Antibiotic treatment began 5 days prior to ortho-
topic cell injection and was maintained throughout animal experiments.
Commensal administration
Faecalibaculum rodentium (DSMZ, Type strain 103405) was cultured in Peptone Yeast Glucose (PYG) broth
and harvested at optical density (OD) 0.6, via centrifugation (2770 rcf, 10 min, 4C). Pellets were washed
twice in Phosphate Buffered Saline (PBS) before final resuspension in PBS. Bacteria were administered
three times per week by oral gavage (250 mL).
Cromolyn administration
Animals were treated with VNMAA antibioitcs three times weekly and orthotopically induced with a PyMT-
BO1 BrCa as described previously. From 10 days post tumor induction, animals received a daily intraper-
itoneal injection of cromolyn sodium (Merck Life Science) (10 mg/kg, 100 mL) alongside continued oral
antibioitcs until experimental cessation 15 days after tumor induction.
Breast cancer cell culture
Cells were cultured in high glucose DMEM (Thermofisher, Carlsbad, California, US) supplementedwith 10%
fetal bovine serum (FBS) (Hyclone, Thermofisher) and 100 units/mL penicillin/streptomycin (Pen/Strep)
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(Thermofisher). Cells were maintained at 37C and 5% CO2. Tissue culture plastic was coated with 0.1%
porcine gelatin (Merck Life Science) in water for 1 hr at 37C prior to culture.
PyMT-BO1, BRPKp110 and EO771 tumor growth assays
PyMT-BO1 or EO771 (13105) cells or BRPKp110 (53105) cells were injected at 50mL per animal at a 1:1
mixture of PBS andMatrigel (Corning Life Sciences, Corning, New York, USA) into the left abdominal mam-
mary fat pad (MFP) of age matched female mice. At experimental endpoint, animals were sacrificed by
cervical dislocation and tissues harvested for various downstream analyses. Tumors were measured in
two dimensions (Length x Width) using digital calipers. Tumor volume was calculated according to the
following formula: (length 3 width2 3 0.52 (Tomayko and Reynolds, 1989).
Spontaneous breast cancer model (for mast cell counts)
Delta16HER2 transgenic FVB mice (Castagnoli et al., 2014; Marchini et al., 2011) were treated with Vanco-
mycin (200 mg/L) in drinking water starting when mice were 4 weeks of age and continued to 6 weeks post
tumor onset.
ER+ Luminal A breast cancer model (for mast cell counts)
Mice were orally gavaged (100 mL) for 14 days with antibiotic cocktail (0.5 mg/mL Vancomycin, 1 mg/mL
Ampicillin, 1 mg/mL Metronidazole, 1 mg/mL Neomycin, and 1 mg/mL Gentamicin) or water. After
14 days of treatment, mice were left untreated for four days before initiation of mammary tumors, at which
point 53105 BRPKp110 cells were injected orthotopically into the abdominal mammary fat pad, as previ-
ously described (Buchta Rosean et al., 2019).
Passive FMT
Animals were not directly co-housed due to delivery of Ampicillin via drinking water, but co-housing was
simulated by transfer of bedding and fecal pellets between cages. The antibiotic treatment regimen was
followed as before, beginning five days prior to orthotopic cell injection, during which time animals
from each experimental condition were housed separately. At tumor injection, water and VNMAA treated
animals were provided bedding swaps. This was maintained throughout the experiment with bedding
swaps every other day and antibiotic treatments were also continued throughout the experiment.
METHOD DETAILS
Cryo-sectioning of snap frozen tumors
Tumors were harvested from humanely killed animals, immediately placed in microcentrifuge tubes, snap
frozen in liquid nitrogen and stored at 80C. Tumors were subsequently sectioned at a thickness of 5mm
on a Cryostat NX70 (Thermofisher) and sections were stored at 80C until staining.
Tissue processing (for H&E and IHC staining)
Tissues were fixed overnight in 4% paraformaldehyde (PFA) and paraffin-embedded before being cut in
6 mm sections. Sections were deparaffinised and rehydrated in xylene followed by graded alcohol solutions
to PBS prior to any subsequent staining.
H&E staining
Using a Leica ST5020 multistainer (Leica Biosystems, Milton Kenes, UK), sections were placed in Harris He-
matoxylin (Merck Life Science) for five minutes followed by acid alcohol (70% ethanol, 1% hydrochloric acid)
for 15 s, 0.1% sodium carbonate for 1 min and eosin (Merck Life Science-Adrich) for 30 s. Sections were then
subject to a graded alcohol dehydration to xylene prior to mounting in an anhydrous mounting medium.
Toluidine blue staining
Frozen sections were air dried for 10 min at room temperature (RT) then fixed in ice-cold methanol for
10 min. Post-fixation, sections underwent three 2min washes in distilled water before being placed in work-
ing toluidine blue solution for 3 min (working solution:Toluidine Blue O (Merck) was prepared in 70%
ethanol and then added to 1%NaCl, pH 2.5 in a ratio of 1:10). Following staining, sections underwent three
2 min washes in distilled water followed by a gradual dehydration through 95% and 100% ethanol before
being cleared in xylene and mounted using an anhydrous mounting medium.
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Frozen sections were air dried for 10 min at RT then fixed in 4% PFA for 10 min. Sections were covered with
Picro-Sirius Red solution (Abcam, Cambridge, UK) and incubated for 60 min at RT. Sections were then
washed twice in a 0.5% solution of acetic acid, dehydrated in three changes of 100% ethanol and cleared
in xylene before being mounted mounting in an anhydrous mounting medium. Fibrosis was quantified us-
ing Image J software by calculating the area of tissue and the intensity of red staining.
Immunohistochemistry
Paraffin-embedded sections were blocked for endogenous peroxidases (3% H2O2 in methanol) prior to a
citrate buffered antigen retrieval and blocking in a Tris-buffered saline (TBS), 10% goat serum, 0.1% Triton-
X100 solution. Staining was performed using either polyclonal rabbit anti-Ki67 antibody (Abcam) or mono-
clonal rat anti-endomucin (Santa Cruz Biotechnology, Heidelberg, Germany) both at 1:1000 overnight at
4C. Following a one-hour incubation with either a HRP conjugated anti-rabbit or anti-rat immunoglobulins
(Agilent, Santa Clara, CA, USA) sections were developed with 3,30-Diaminobenzidine (DAB) chromogen
and quenched in water. Harris Hematoxylin (Merck Life Science) was used to counterstain prior to a graded
alcohol dehydration and mounting in an anhydrous mounting medium. Quantification of the number of
Ki67-positive cells was performed by an average count of two frames per tumor section expressed as a per-
centage of total cells per frame.
Flow cytometry
Organs were excised from humanely killed animals and tissues were mechanically homogenized using scal-
pels. Homogenate was incubated in collagenase solution (0.2% Collagenase IV (Thermofisher), 0.01% Hy-
aluronidase (Merck Life Science) & 2.5 U/ml DNAse I (Merck Life Science) in Hank’s Balanced Salt Solution
(HBSS) for 1 hr at 37C with regular agitation. Supernatant was passed through a 70 mm cell strainer and
centrifuged for 5 min at 300 x g/4C. The pellet was washed twice in PBS and resuspended in 10 mL 1X
red blood cell lysis buffer (Thermofisher) and incubated for 5 min at RT. Cells were washed once in PBS,
counted using a hemocytometer and 1 million cells per condition transferred to a 96 well plate for staining.
Cells were incubated in a fixable Live/Dead stain (Thermofisher) for 30 min at RT, washed twice and blocked
in Fc Block (Miltenyi, Bergisch Gladbach, Germany) made in FACS buffer (1% FBS in PBS) for 10 min at 4C.
Cells were resuspended in 100mL antibody solutions and incubated at 4C for 30 min in the dark. For cell
surface only staining, cells were incubated in 4% PFA for 30 min, washed once in PBS and stored at 4C until
analyzed. If intracellular staining was required, cells were incubated in FoxP3 fixation/permeabilisation
buffer (Thermofisher) overnight at 4C, washed twice in 1X permeabilisation buffer (Thermofisher), blocked
in 5% normal rat serum for 30 min at RT and stained in the relevant antibody diluted in 1X permeabilisation
buffer for 30 min at RT in the dark. Cells were washed twice in 1X permeabilisation buffer, then finally re-
suspended in FACS buffer and stored at 4C until analyzed.
All data was collected using a Becton Dickinson (BD, Franklin Lakes, NJ, USA) LSR Fortessa with standard
filter sets and five lasers. Data was analyzed using FlowJo software (BD).
For all samples, single cells were gated via FSC-A against FSC-H followed by live cell selection as a Live/
Dead negative population and leukocytes through CD45+ staining. Pan-myeloid cells were gated as
CD11b+ and subsequent populations including monocytic (Ly6C+), neutrophilic (Ly6G+) and macro-
phages (F4/80+) were identified from them. Macrophage activation was defined as ‘M1’ (MHCII+) or
‘M2’ (CD206+) from the F4/80+ population. Lymphocytes (CD3e+) were gated from a CD45+ population
and divided into CD8+ and CD4+ populations with the CD4 population being further classified into T-reg-
ulatory cells though Foxp3+ staining. B-Cells (CD19+) were also gated directly from CD45+ populations.
Gating strategies are detailed in Figure S3A.
Caecal DNA extraction
Caecal material or feces was weighed into MPBio Lysing Matrix E bead beating tubes (MPBio, Santa Ana,
CA, USA) and extraction was completed according to the manufacturer’s protocol for the MPBio
FastDNA SPIN Kit for Soil but extending the beat beating time to 3 min. The DNA recovered from these
samples was assessed using a Qubit 2.0 fluorometer (Thermofisher).
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A modified Illumina Nextera low input tagmentation approach was used. 9 mL of TD Tagment DNA Buffer
was mixed with 0.09 mL TDE1, Tagment DNA Enzyme and 4.01 mL PCR grade water in a master mix and 3 mL
added to a chilled 96 well plate. Genomic DNA was normalized to 0.5ng/mL with 10 mM Tris-HCl. 2 mL of
normalized DNA (1ng total) was pipette mixed with the 5 mL of the tagmentation mix and heated to 55 C
for 10 min in a PCR block.
A PCR master mix was made up using 4 ul kapa2G buffer, 0.4 mL dNTP’s, 0.08 mL Polymerase and 4.52 mL
PCR grade water, contained in the Kap2G Robust PCR kit (Merck Life Science) per sample and 9 mL added
to each well need to be used in a 96-well plate. 2 mL of each P7 and P5 of Nextera XT Index Kit v2 index
primers (Illumina) were added to each well. Finally, the 7 mL of Tagmentation mix was added and mixed.
The PCR was run with 72C for 3 min, 95C for 1 min, 14 cycles of 95C for 10s, 55C for 20s and 72C for
3 min.
Following the PCR reaction, the libraries were quantified using the Quant-iT dsDNA Assay Kit, high sensi-
tivity kit and run on a FLUOstar Optima plate reader. Libraries were pooled following quantification in equal
quantities. The final pool was double-SPRI size selected between 0.5 and 0.7X bead volumes using KAPA
Pure Beads (Roche, Burgess Hill, UK). The final pool was quantified on a Qubit 3.0 instrument and run on a
D5000 ScreenTape (Agilent) using the Agilent Tapestation 4200 to calculate the final library pool molarity.
The pool was run at a final concentration of 1.5 pM on an Illumina Nextseq500 instrument using a Mid
Output Flowcell (NSQ 500 Mid Output KT v2(300 CYS) following the Illumina recommended denaturation
and loading recommendations which included a 1% PhiX spike in (PhiX Control v3 Illumina Catalog FC-110-
3001). Data was uploaded to Basespace (www.basespace.illumina.com) where the raw data was converted
to 8 FASTQ files for each sample.
Human and mouse contamination was removed from raw reads by using Kraken2 v2.1.0 (1) with a con-
fidence setting of 0.5 and minimum base quality 22 using the human genome GRCh38.p12 and mouse
genome GRCm39 as reference databases. Decontaminated reads were trimmed to a quality of phred
20 and adapters removed using fastp v0.21.0 (2) and PhiX Illumina standards were removed with
BBDuk v38.76 (sourceforge.net/projects/bbmap/). Clean reads from single samples were concate-
nated. Taxonomic profiling was performed on the filtered reads using MetaPhlAn v3.0 using the set-
tings –unknown_estimation and –add_viruses and the Chocophlan database v30 (3). Functional
profiling was performed with HUMAnN2 v3.0.0.alpha with search mode uniref90 and an uniref90 trans-
lated search database and using DIAMOND v0.9.24 (4). The results were normalized to relative
abundances.
Relative abundances of taxa and pathways were analyzed in R (R Core Team 2013) and visualized using the
ggplot2 package (5). To test whether relative abundances of F. rodentium were significantly different in
treatments VNMAA and Cephalexin compared to controls, we performed the Wilcoxon-Mann-Whitney
test using thewilcox_test function in the coin package v1.4-1 (6). p values were adjusted for multiple testing
using the Benjamini-Hochberg correction within the function p.adjust of the stats package v3.6.2. To deter-
mine bacterial species that were differentially abundant in the Cephalexin treatment compared to controls
we pre-filtered the species table to remove taxa that were not detected one of the two experiments; not
found in more than 5 samples; and those that had a coefficient of variation below 1. On the remaining
22 species we performedWilcoxon-Mann-Whitney tests using the wilcox_test function in the coin package
and adjusted the p value for multiple testing using the Benjamini-Hochberg correction within the function
p.adjust of the stats package. Functional pathways were filtered and their relative abundances analyzed
identically to species abundances (Beghini et al., 2021; Buchfink et al., 2015; Chen et al., 2018; University
of California Los Angeles. Department of Statistics. and Foundation for Open Access Statistics.; Wickham,
2016; Wood et al., 2019). To visualize the magnitude and direction of change of functional pathways be-
tween treatments, sample difference between medians and their confidence intervals were extracted
from the Wilcoxon-Mann-Whitney test results using the confint() from the coin package. These values
were plotted and colored according to adjusted p values using the ggplot2 package. The deviation
from an estimate of zero indicates direction of change with pathways enriched in cephalexin treatments
to the right and pathways enriched in controls to the left side (Figure S6).
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Caecal contents (50–100 mg) were thoroughly mixed with 600–1200 mL NMR buffer made up of 0.1 M phos-
phate buffer (0.51 gNa2HPO4, 2.82 g K2HPO4, 100mg sodium azide and 34.5mg sodium 3-(Trimethylsilyl)-
propionate-d4 (1 mM) in 200 mL deuterium oxide), centrifuged at 12,000 x g for 5 min at 4C and superna-
tant transferred to 5-mm NMR tubes. 1H NMR spectra were recorded on a 600MHz Bruker Avance spec-
trometer fitted with a 5 mm TCI cryoprobe (Bruker, Rheinstetten, Germany). Sample temperature was
controlled at 300 K. Each spectrum consisted of 64 scans of 65,536 complex data points with a spectral
width of 12.5 ppm (acquisition time 2.67 s). The noesypr1d presaturation sequence was used to suppress
the residual water signal with low power selective irradiation at the water frequency during the recycle
delay (D1 = 3 s) and mixing time (D8 = 0.01 s). A 90 pulse length of 9.6 ms was set for all samples. Spectra
were manually phased, and baseline corrected using the TOPSPIN 2.0 software. Metabolites were identi-
fied and quantified using Chenomx  software NMR suite 7.0TM.
Statistical analysis and heatmapping of metabolite concentrations was performed usingQlucoreOmics Ex-
plorer 3.6 software.
Mesoscale discovery multiplex arrays
Tissue samples were weighed into aMPBio LysingMatrix E bead beating tube (MPBio) with 1mL of homog-
enization buffer (PBS +10% fetal bovine serum (FBS) (Thermofisher) + cOmplete protease inhibitor
(Roche). Tissues were homogenized using an MPBio Fast Prep bead beater at speed 4.0 for 40 s followed
by speed 6.0 for 40 s. Samples were centrifuged at 12,000 x g for 12 min at 4C and subsequently stored at
80C until analyzed. Samples were run on a Mesoscale Discovery (MSD, Rockville, MD, USA) V-PLEX Pro-
Inflammatory Panel 1 Mouse Kit according to the manufacturer’s instructions. Plate was read using an MSD
QuickPlex SQ 120 imager.
Whole tumor RNA sequencing
Frozen tissue was defrosted at 4C and briefly homogenized using a scalpel. The homogenate was trans-
ferred to anMPBio Lysing Matrix E bead beating tube containing RNAbee (AMSBio, Cambridge, MA, USA)
and homogenized using a TissueLyser LT. Extraction of RNA was performed using a phenol/choloroform
method followed by purification of RNA using the SV Total RNA Isolation System (Promega) according
to manufacturer’s instructions. RNA concentration and purity was analyzed on a Nanodrop 2000 system
(Thermofisher) to assess A260/280 and A260/230 ratios. Extracted RNAwas then quality checked and quan-
tified using a 2100 Bioanalyzer (Agilent) with an RNA 6000 Nano analysis kit (Agilent) and any samples with a
RIN value of >8 were considered for use in sequencing. Suitable samples were sent to the Wellcome Trust
Sanger Institute for sequencing. All samples were processed by poly-A selection and then sequenced using
non-stranded, paired end protocol. Initial processing was performed at Welcome Trust Sanger Institute as
follows. Data demultiplexed and adapter removed. Raw reads quality controlled using FastQC (0.11.3) and
trimmed (phred score > 30) using FASTX (0.1.5). This was followed by read alignment to mouse reference
genome (NCBI Mus musculus GRCm38) using Tophat (2.1.1) using maximum intron size 500.000 bp and
default settings. Aligned transcripts were assembled and quantified using Cufflinks (2.1.0) (applying stan-
dard parameters).
Read alignment and quantification was performed using Kallisto. The quantified read data was then
normalized and differential expression analysis was conducted using DeSeq2. Transcript IDs were anno-
tated using the Ensembl Biomart database. Significantly up and downregulated genes (padj < 0.05) were
used to perform biological process and pathway analysis using DAVID. Biological processes were anno-
tated according to the GO_TERM_BP_ALL database and pathway analysis was performed using KEGG
pathways. Significantly enriched pathways were determined by an enrichment score of less than 0.05, how-
ever scores of less than 0.1 were also evaluated as non-significantly altered pathways and processes.
Single cell RNA sequencing
Organs were excised from humanely killed animals and tissues were mechanically homogenized using
scalpels. Homogenate was incubated in collagenase solution (0.2% Collagenase IV (Thermofisher),
0.01% Hyaluronidase (Merck Life Science) & 2.5 U/ml DNAse I (Merck Life Science) in HBSS) for 1 hr at
37C with regular agitation. Supernatant was passed through a 70 mm cell strainer and centrifuged for
5 min at 300 x g/4C. Pellet was washed twice in PBS and resuspended in 10mL 1X red blood cell lysis buffer
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(Thermofisher) and incubated for 5 min at RT. Cells were washed once in PBS and resuspended in 10mL of
1% FBS in PBS before being handed to the Earlham Institute sequencing facility where they were run on the
10X GenomicsTM Chromium platform.
BCL files were processed using bcl2fastq to create FASTQ files which were demultiplexed using Cell
Ranger v2.0 aligned to the mm10 (GRCm38) mouse transcriptome and their = cell and unique molecular
identifier (UMI) barcodes extracted. The resulting digital gene expression DGE matrices were processed
using the R package Seurat V3.0 (Stuart et al., 2019). As a quality control step, the DGE matrices were
filtered to remove low-quality cells (genes detected in less than five cells and cells where < 200 genes
had non-zero counts) and library size normalization to obtain the normalized counts.
Datasets were integrated in Seurat v3.0 (Stuart et al., 2019) using a non-linear transformation of the under-
lying data and identified anchors from FindIntegrationAnchors used to integrate across the datasets. The
top 2500 highly variable genes were selected and the integrated dataset was scaled. Initial clustering was
performed using a Louvain algorithm with default parameters within Seurat’s FindClusters function (Stuart
et al., 2019) and a single PCA applied to both datasets to project onto two dimensions with UMAP
clustering.
Differential expression analysis was performed using combined data from the four datasets. Genes were
identified as differentially expressed in each cluster by comparing the gene expression of cells in the cluster
with that of all the other cells. The top differentially expressed genes for each cluster were identified as clus-
ter marker genes and ranked by their adjusted p values and average log-fold change. The top cluster
marker genes were compared to cell type marker genes identified in the literature and used for cell-
type identification (Han et al., 2018; Tabula Muris et al., 2018; Wagner et al., 2019).
QUANTIFICATION AND STATISTICAL ANALYSIS
Unless otherwise noted, data as normally distributed and p values were generated using Student’s t test
(GraphPad Prism, version 9.1) (unpaired, two-tailed, at 95% confidence interval) or One-way ANOVA where
appropriate. p values are indicated directly in the figures; ns = not significant (P > 0.05).
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